CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 rec...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Linchun Jin, Haipeng Tao, Aida Karachi, Yu Long, Alicia Y. Hou, Meng Na, Kyle A. Dyson, Adam J. Grippin, Loic P. Deleyrolle, Wang Zhang, Didier A. Rajon, Qiong J. Wang, James C. Yang, Jesse L. Kresak, Elias J. Sayour, Maryam Rahman, Frank J. Bova, Zhiguo Lin, Duane A. Mitchell, Jianping Huang
Format: article
Langue:EN
Publié: Nature Portfolio 2019
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/de9a908e5e6e46b0b45bc79a9225470e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 receptors that mediate their migration into the tumor microenvironment when IL-8 production in tumor is naturally expressed or enhanced by radiation.

Documents similaires